Literature DB >> 27662545

Long-term body composition changes in antiretroviral-treated HIV-infected individuals.

Philip M Grant1, Douglas Kitch, Grace A McComsey, Ann C Collier, Benedetta Bartali, Susan L Koletar, Kristine M Erlandson, Jordan E Lake, Michael T Yin, Kathy Melbourne, Belinda Ha, Todd T Brown.   

Abstract

OBJECTIVE: Body composition impacts physical function and mortality. We compared long-term body composition changes after antiretroviral therapy (ART) initiation in HIV-infected individuals to that in HIV-uninfected controls.
DESIGN: Prospective observational study.
METHODS: We performed dual-energy x-ray absorptiometry (DXA) approximately 7.5 years after initial DXA in available HIV-infected individuals who received DXAs during the randomized treatment trial AIDS Clinical Trials Group A5202. For controls, we used DXA results from HIV-uninfected participants in the Boston Area Community Health/Bone and Women's Interagency HIV Study cohorts. Repeated measures analyses compared adjusted body composition changes between HIV-infected and HIV-uninfected individuals. Multivariable analyses evaluated factors associated with body composition change in HIV-infected individuals.
RESULTS: We obtained DXA results in 97 HIV-infected and 614 HIV-uninfected participants. Compared with controls, HIV-infected individuals had greater adjusted lean mass and total, trunk, and limb fat gain during the first 96 weeks of ART. Subsequently, HIV-infected individuals lost lean mass compared with controls. Total, trunk, and limb fat gains after 96 weeks of ART slowed in HIV-infected individuals but remained greater than in controls. Lower CD4 T-cell count was associated with lean mass and fat gain during the initial 96 weeks of ART, but subsequently no HIV-related characteristic was associated with body composition change.
CONCLUSION: Consistent with a 'return to health effect', HIV-infected individuals, especially those with lower baseline CD4 T-cell counts, gained more lean mass and fat during the first 96 weeks of ART than HIV-uninfected individuals. Continued fat gain and lean mass loss after 96 weeks may predispose HIV-infected individuals to obesity-related diseases and physical function impairment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27662545      PMCID: PMC5101158          DOI: 10.1097/QAD.0000000000001248

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  24 in total

1.  Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy.

Authors:  Carl Grunfeld; Michael Saag; Joseph Cofrancesco; Cora Elizabeth Lewis; Richard Kronmal; Steven Heymsfield; Phyllis C Tien; Peter Bacchetti; Michael Shlipak; Rebecca Scherzer
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

2.  A new frailty syndrome: central obesity and frailty in older adults with the human immunodeficiency virus.

Authors:  Krupa Shah; Tiffany N Hilton; Lauren Myers; Jonathan F Pinto; Amneris E Luque; William J Hall
Journal:  J Am Geriatr Soc       Date:  2012-02-08       Impact factor: 5.562

3.  Longitudinal changes in body composition associated with healthy ageing: men, aged 20-96 years.

Authors:  Andrew S Jackson; Ian Janssen; Xuemei Sui; Timothy S Church; Steven N Blair
Journal:  Br J Nutr       Date:  2011-08-03       Impact factor: 3.718

4.  Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.

Authors:  Grace A McComsey; Douglas Kitch; Paul E Sax; Pablo Tebas; Camlin Tierney; Nasreen C Jahed; Laurie Myers; Kathleen Melbourne; Belinda Ha; Eric S Daar
Journal:  Clin Infect Dis       Date:  2011-07-15       Impact factor: 9.079

5.  Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study.

Authors:  Jason Reingold; Christine Wanke; Donald Kotler; Cora Lewis; Russell Tracy; Steven Heymsfield; Phyllis Tien; Peter Bacchetti; Rebecca Scherzer; Carl Grunfeld; Michael Shlipak
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

6.  Estimates of body composition with dual-energy X-ray absorptiometry in adults.

Authors:  Chaoyang Li; Earl S Ford; Guixiang Zhao; Lina S Balluz; Wayne H Giles
Journal:  Am J Clin Nutr       Date:  2009-10-07       Impact factor: 7.045

7.  Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.

Authors:  Grace A McComsey; Carlee Moser; Judith Currier; Heather J Ribaudo; Pawel Paczuski; Michael P Dubé; Theodoros Kelesidis; Jennifer Rothenberg; James H Stein; Todd T Brown
Journal:  Clin Infect Dis       Date:  2016-01-20       Impact factor: 9.079

8.  Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals.

Authors:  Philip M Grant; Douglas Kitch; Grace A McComsey; Ann C Collier; Susan L Koletar; Kristine M Erlandson; Michael T Yin; Benedetta Bartali; Belinda Ha; Kathy Melbourne; Todd T Brown
Journal:  J Infect Dis       Date:  2016-06-20       Impact factor: 5.226

9.  Long-term impact of HIV wasting on physical function.

Authors:  Kristine M Erlandson; Xiuhong Li; Alison G Abraham; Joseph B Margolick; Jordan E Lake; Frank J Palella; Susan L Koletar; Todd T Brown
Journal:  AIDS       Date:  2016-01-28       Impact factor: 4.177

10.  Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

Authors:  Richard H Haubrich; Sharon A Riddler; A Gregory DiRienzo; Lauren Komarow; William G Powderly; Karin Klingman; Kevin W Garren; David L Butcher; James F Rooney; David W Haas; John W Mellors; Diane V Havlir
Journal:  AIDS       Date:  2009-06-01       Impact factor: 4.177

View more
  37 in total

1.  Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.

Authors:  Kristine M Erlandson; Suzanne P Fiorillo; Sandra Wagner Cardoso; Cynthia Riviere; Jorge Sanchez; James Hakim; Nagalingeswaran Kumarasamy; Sharlaa Badal-Faesen; Umesh Lalloo; Johnstone Kumwenda; Thomas B Campbell; Todd T Brown
Journal:  AIDS Res Hum Retroviruses       Date:  2017-05-16       Impact factor: 2.205

2.  Abdominal obesity, sarcopenia, and osteoporosis are associated with frailty in men living with and without HIV.

Authors:  Kellie L Hawkins; Long Zhang; Derek K Ng; Keri N Althoff; Frank J Palella; Lawrence A Kingsley; Lisa P Jacobson; Joseph B Margolick; Jordan E Lake; Todd T Brown; Kristine M Erlandson
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

Review 3.  Geriatric syndromes: new frontiers in HIV and sarcopenia.

Authors:  Kellie L Hawkins; Todd T Brown; Joseph B Margolick; Kristine M Erlandson
Journal:  AIDS       Date:  2017-06-01       Impact factor: 4.177

4.  Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE.

Authors:  Triin Umbleja; Todd T Brown; Edgar T Overton; Heather J Ribaudo; Jennifer A Schrack; Kathleen V Fitch; Pamela S Douglas; Steven K Grinspoon; Sarah Henn; Roberto C Arduino; Benigno Rodriguez; Constance A Benson; Kristine M Erlandson
Journal:  J Infect Dis       Date:  2020-07-09       Impact factor: 5.226

Review 5.  Sarcopenia in people living with the Human Immunodeficiency Virus: a systematic review and meta-analysis.

Authors:  Vitor H F Oliveira; Ana L Borsari; Allison R Webel; Kristine M Erlandson; Rafael Deminice
Journal:  Eur J Clin Nutr       Date:  2020-04-27       Impact factor: 4.016

6.  Lean mass declines consistently over 10 years in people living with HIV on antiretroviral therapy, with patterns differing by sex.

Authors:  Paula Debroy; Jordan E Lake; Myung Sim; Kristine M Erlandson; Julian Falutz; Carla M Prado; Todd T Brown; Giovanni Guaraldi; The Modena Hiv Metabolic Cohort Team
Journal:  Antivir Ther       Date:  2019

7.  Antiretroviral initiation is associated with increased skeletal muscle area and fat content.

Authors:  Kristine M Erlandson; Suzanne Fiorillo; Fadzai Masawi; Ann Scherzinger; Grace A McComsey; Jordan E Lake; James H Stein; Judith S Currier; Todd T Brown
Journal:  AIDS       Date:  2017-08-24       Impact factor: 4.177

Review 8.  Benefits and Risks of Statin Therapy in the HIV-Infected Population.

Authors:  Mosepele Mosepele; Onkabetse J Molefe-Baikai; Steven K Grinspoon; Virginia A Triant
Journal:  Curr Infect Dis Rep       Date:  2018-05-26       Impact factor: 3.725

9.  CT Fat Density Accurately Reflects Histologic Fat Quality in Adults With HIV On and Off Antiretroviral Therapy.

Authors:  Jordan E Lake; Carlee Moser; Liz Johnston; Clara Magyar; Scott D Nelson; Kristine M Erlandson; Todd T Brown; Grace A McComsey
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

10.  Low thigh muscle mass is associated with coronary artery stenosis among HIV-infected and HIV-uninfected men: The Multicenter AIDS Cohort Study (MACS).

Authors:  Martin Tibuakuu; Di Zhao; Ankita Saxena; Todd T Brown; Lisa P Jacobson; Frank J Palella; Mallory D Witt; Susan L Koletar; Joseph B Margolick; Eliseo Guallar; Sai Krishna C Korada; Matthew J Budoff; Wendy S Post; Erin D Michos
Journal:  J Cardiovasc Comput Tomogr       Date:  2018-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.